Evidence map›Paper›PMID 37509435›Full record

ArticleBiomedicines2023

Adjuvant Effect of Whole-Cell Pertussis Component on Tetanus Toxoid Potency in Murine Model.

Marta Prygiel, Ewa Mosiej, Karol Wdowiak, Daniel Rabczenko, Aleksandra Anna Zasada

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Microorganisms · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Marta PrygielDepartment of Sera and Vaccines Evaluation, National Institute of Public Health NIH-National Research Institute, Chocimska 24, 00-791 Warsaw, Poland.ORCID 0000-0001-9856-0767
Ewa MosiejDepartment of Sera and Vaccines Evaluation, National Institute of Public Health NIH-National Research Institute, Chocimska 24, 00-791 Warsaw, Poland.
Karol WdowiakDepartment of Sera and Vaccines Evaluation, National Institute of Public Health NIH-National Research Institute, Chocimska 24, 00-791 Warsaw, Poland.
Daniel RabczenkoDepartment-Center for Monitoring and Analyses of Population Health Status, National Institute of Public Health NIH-National Research Institute, Chocimska 24, 00-791 Warsaw, Poland.ORCID 0000-0002-9746-2003
Aleksandra Anna ZasadaDepartment of Sera and Vaccines Evaluation, National Institute of Public Health NIH-National Research Institute, Chocimska 24, 00-791 Warsaw, Poland.ORCID 0000-0003-2774-0941
Narodowy Instytut Zdrowia Publicznego PZH – Państwowy Instytut Badawczy · PL

Funding

NIPH NIH - NRI 1BSBW/19NIPH NIH - NRI 2BSBW/19
6 · The paper itself

Abstract

There is currently an increasing interest in the development of new-generation purified antigen-based vaccines with a higher safety profile compared to conventional inactivated vaccines. The main problem of subunit vaccines is their lower immunogenicity compared to whole-cell vaccines and inducing weaker and shorter-lasting immune responses. In this paper, the results of the assay of the potency of the tetanus component combined with the diphtheria component and whole-cell pertussis vaccine (DTwP), diphtheria and tetanus vaccine (DT), and in monovalent tetanus vaccine (T) are presented. In the mice model, an adjuvant impact of the whole-cell pertussis component on the immune response against tetanus was observed. It was noticed that the potency of tetanus component in the DTwP vaccine was significantly higher than tetanus potency in DT and T vaccines, despite the same bounding ability unit of the tetanus toxoid in the vaccine formulations. The levels of induction of tetanus antibodies by the tested vaccines were also examined. There were no differences in the induction of humoral responses against tetanus by tested vaccines. This publication discusses the possible mechanisms of impact of the whole-cell pertussis component on the other vaccine antigens and the positive and negative aspects of using the whole-cell pertussis component as an adjuvant.

Indexed as

adjuvantcontrol laboratorydiphtheriapertussistetanusvaccines

Identifiers

PMID37509435
PMCPMC10376220
OpenAlexW4382135337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.